Juvederm XC received FDA clearance last week, as pharmaceutical co. Allergan Inc cited positive results from clinical trials where over 90 percent of the 36 participants reported a more comfortable procedure with the new formulation.
Juvederm XC is the latest addition in the wave of fillers released in the U.S. that contain lidocaine, an anesthetic said to numb the treatment area within seconds. The first wrinkle filler of this kind, Prevelle Silk, was approved in 2008. However, physicians weren’t so eager to jump on the lidocaine-bandwagon 2 years ago.
“The issue with a hyaluronic acid filler with lidocaine is that it doesn’t work until you actually start injecting patients, and these injections are so quick, by the time the lidocaine takes effect, you’re almost finished” said Dr. Joe Niamtu to Cosmetic Surgery Times.
Despite the positive results cited by the pharmaceutical company, it may take some time for Juvederm XC to gain approval, and even then I wouldn’t expect surgeons to abandon traditional pain control methods like dental blocks and numbing cream, which are actually very effective.
The safety profile and effectiveness (typically for treating nasolabial folds) is similar for both Juvederm and the new Juvederm XC.